Pew Responds to White House's Drug Pricing Blueprint Information Request

Comments address administration’s questions on how federal, manufacturer programs affect spending

The White House's Drug Pricing Blueprint

The Pew Charitable Trusts sent a letter July 16 to the U.S. Department of Health and Human Services, offering comments on the Trump administration’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Request for Information (RFI).

Pew’s response to the RFI addresses the following topics:

  • Federal program incentives.
  • Drug pricing structures and incentives.
  • Proposals to reform the Medicare Part B Competitive Acquisition Program.
  • Price reporting requirements and incentive structures.
  • Cost-shifting and cross-subsidization.
  • Generic drug pricing and development.
  • Pharmacy benefit managers and rebates.
  • 340B Drug Pricing Program.
  • Patient cost-sharing.
The front facade of the Supreme Court of the United States in Washington, DC.

Agenda for America

Resources for federal, state, and local decision-makers

Quick View

Data-driven policymaking is not just a tool for finding new solutions for emerging challenges, it makes government more effective and better able to serve the public interest.